Neumifil nasal spray heads to COPD Phase 2 trial with new investments
Pneumagen has secured £8 million (nearly $10 million) in investments to support the clinical development of its nasal spray, called Neumifil, for the prevention and treatment of virus-induced exacerbations in people with chronic obstructive pulmonary disease (COPD). “We are very pleased to announce this funding from our existing…